ArticleJournal of thrombosis and thrombolysis2026
Integrative transcriptomic analysis identifies an oxidative stress-associated diagnostic signature for myocardial infarction.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Reactive oxygen species (ROS) play a pivotal role in myocardial infarction (MI), contributing to oxidative stress, inflammation, and tissue remodeling. However, ROS-related gene signatures with diagnostic and mechanistic relevance in MI remain insufficiently defined. Transcriptomic data from six MI cohorts were integrated, with GSE66360 as the training set and five datasets as external validation. Batch correction was performed using ComBat. ROS pathway activity was assessed by single-sample gene set enrichment analysis (ssGSEA). Differentially expressed genes (DEGs) shared across datasets were intersected with ROS-related genes to construct an elastic net logistic regression model. Model performance was evaluated using ROC, calibration, and decision curve analysis. SHAP analysis was conducted for interpretability. Upstream transcription factor and miRNA interactions were predicted, and single-gene GSEA was used to explore biological pathways. Immune infiltration and checkpoint expression were analyzed using multiple deconvolution algorithms. Human AC16 cardiomyocytes were used to explore the functions of ADAM9 in MI. To validate our findings in vivo, we established the mice MI model and performed histology, immunostaining, and qRT-PCR to examine the six signature genes. ROS pathway activity was consistently elevated in MI samples across all cohorts. A six-gene signature (MMP9, ADAM9, BST1, TLR4, CLEC7A, CYP1B1) showed strong diagnostic performance. SHAP analysis identified MMP9 as the top contributor. Regulatory network analysis highlighted NFKB1, STAT1, and miR-21-5p as upstream regulators. Functional enrichment revealed an association with inflammatory and immune pathways. Software algorithm predictions from patient blood cell samples showed that the MI sample exhibited increased infiltration of macrophages, dendritic cells, and fibroblasts, along with upregulation of immune and inflammatory genes. Several model genes correlated positively with endothelial cell infiltration. Function studies in human AC16 cardiomyocytes suggested that ADAM9 inhibited cardiomyocyte survival and enhanced oxidative stress. Experimental validation confirmed that all six genes were significantly upregulated at both mRNA and protein levels in infarcted mouse hearts. We identified a ROS-related six-gene diagnostic signature for MI, with strong performance and mechanistic links to immune activation and vascular remodeling. This model may aid early diagnosis and provide insight into redox-immune interplay in MI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.